Bader Andreas G, Brown David, Winkler Matthew
Mirna Therapeutics, Inc. and Asuragen, Inc., Austin, TX 78744, USA.
Cancer Res. 2010 Sep 15;70(18):7027-30. doi: 10.1158/0008-5472.CAN-10-2010. Epub 2010 Aug 31.
MicroRNAs (miRNA), a class of natural RNA-interfering agents, have recently been identified as attractive targets for therapeutic intervention. The rationale for developing miRNA therapeutics is based on the premise that aberrantly expressed miRNAs play key roles in the development of human disease, and that correcting these miRNA deficiencies by either antagonizing or restoring miRNA function may provide a therapeutic benefit. Although miRNA antagonists are conceptually similar to other inhibitory therapies, restoring the function of a miRNA by miRNA replacement is a less well characterized approach. Here, we discuss the specific properties of miRNA replacement and review recent examples that explored the therapeutic delivery of miRNA mimics in animal models of cancer.
微小RNA(miRNA)是一类天然的RNA干扰因子,最近已被确定为具有吸引力的治疗干预靶点。开发miRNA疗法的基本原理基于这样一个前提,即异常表达的miRNA在人类疾病的发展中起关键作用,并且通过拮抗或恢复miRNA功能来纠正这些miRNA缺陷可能会带来治疗益处。虽然miRNA拮抗剂在概念上与其他抑制性疗法相似,但通过miRNA替代来恢复miRNA的功能是一种特征尚不明确的方法。在这里,我们讨论miRNA替代的具体特性,并回顾最近在癌症动物模型中探索miRNA模拟物治疗递送的实例。